Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO --(BUSINESS WIRE)--Aug. 31, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 89,550 shares of its common stock to 12 new employees.
View HTML
Toggle Summary Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q
SAN DIEGO --(BUSINESS WIRE)--Aug. 22, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it received a notice (the “Notice”) on August 17, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC
View HTML
Toggle Summary Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
SAN DIEGO --(BUSINESS WIRE)--Aug. 16, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 .
View HTML
Toggle Summary Biocept Appoints RSM as Independent Auditor
SAN DIEGO --(BUSINESS WIRE)--Jun. 27, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of RSM US LLP (“RSM”) as its independent registered public accounting firm effective June 24, 2022 .
View HTML
Toggle Summary Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial
Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system Assay results will be used to evaluate response to treatment and treatment efficacy for patients enrolling in Plus Therapeutics’
View HTML
Toggle Summary Biocept to Hold Business Strategy Conference Call Today
SAN DIEGO --(BUSINESS WIRE)--Jun. 7, 2022-- Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call today, June 7, 2022 , beginning at 4:00 p.m. Eastern time to discuss its re-focused and rationalized business strategy and to answer questions.
View HTML
Toggle Summary Biocept Reports First Quarter 2022 Financial Results
Net revenues of $19.9 million up 12% over Q1 2021 CNSide™ assay volume up 219% over Q1 2021 and up 70% over Q4 2021 Expanded CNSide customer base with additional oncologists from six leading cancer centers Previews re-focused and rationalized strategy following comprehensive business review
View HTML
Toggle Summary Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
SAN DIEGO --(BUSINESS WIRE)--May 16, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2022 .
View HTML
Toggle Summary Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO --(BUSINESS WIRE)--Apr. 8, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 519,140 shares of its common stock to 44 new employees,
View HTML
Toggle Summary Biocept Reports 2021 Fourth Quarter and Full Year Financial Results
Fourth quarter net revenues of $14.0 million driven by RT-PCR COVID-19 testing volume Full year net revenues of $61.2 million increased 123% over the prior year Positive operating cash flow for 2021 of $3.7 million Cash and cash equivalents at 2021 year-end of $28.9 million CNSide™
View HTML